Coagulation cascade enzymes

The coagulation cascade enzymes are a group of primarily serine proteases that work in a highly regulated, sequential manner to maintain vascular integrity and prevent blood loss through the formation of fibrin clots [1][2]. This cascade is traditionally divided into the extrinsic, intrinsic, and common pathways, where inactive zymogens are converted into active enzymes, ultimately leading to the conversion of prothrombin to thrombin and fibrinogen to fibrin [2][4]. These enzymes are critical therapeutic targets for managing thromboembolic disorders, such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation-related stroke [1][5]. Drugs targeting this system include direct oral anticoagulants (DOACs) that inhibit Factor Xa or thrombin, as well as traditional agents like heparin and warfarin [3][5]. Because these enzymes are essential for normal hemostasis, the primary challenge in therapeutic modulation is balancing the prevention of pathological thrombosis with the risk of life-threatening bleeding [1][6]. Modern drug development has shifted toward more specific inhibitors to improve the safety profile and eliminate the need for constant monitoring [5]. Additionally, these enzymes play roles in inflammation and wound healing, expanding their relevance beyond simple clot formation [2]. Understanding the interplay between these factors is vital for treating both hereditary bleeding disorders like hemophilia and acquired thrombotic states [1].

Other names

Clotting factorsBlood coagulation factorsSerine proteases of the coagulation cascadeHemostatic factors

Drugs targeting the coagulation cascade enzymes primarily act by inhibiting the activity or synthesis of specific factors. This includes direct inhibition of Factor Xa or Thrombin (Factor IIa), indirect inhibition via the activation of antithrombin III, or the antagonism of Vitamin K to prevent the synthesis of functional Factors II, VII, IX, and X [1][5].